Process for the production of a novel endothelin antagonist
US5352800A · kind A · utility
31Cited by
3References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 11, 1993 |
| Grant date | Oct 4, 1994 |
| Priority date | — |
| Expiry date | Mar 11, 2013 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/911
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Fermentation processes for the production of a compound of the Structural Formula I ##STR1## The compound of Structural Formula I has been shown to have endothelin antagonist activity and is therefore useful in treating cardiovascular disorders, such as hypertension, congestive heart failure, postischemic renal failure vasospasm, cerebral and cardia ischemia, myocardial infarction inflammatory diseases, Raynaud's disease, endotoxin shock and asthma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.